Ataxia telangiectasia mutated impacts insulin-like growth factor 1 signalling in skeletal muscle

Experimental Physiology

Volumn 98, Issue 2, 2013, Pages 526-535

  Ching, James Kain ^a   Luebbert, Stephen H ^a   Collins Iv, Roy L ^a   Zhang, Zhihong ^b   Marupudi, Nandhini ^a   Banerjee, Sankha ^a   Hurd, Robin D ^a   Ralston, Lyle ^b,c   Fisher, Jonathan S ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

^b Sigma Aldrich Co   (United States)

^c MONSANTO COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ATM PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; LENTIVIRUS VECTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S6 KINASE; SHORT HAIRPIN RNA; SOMATOMEDIN C;

ALLELE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ATAXIA TELANGIECTASIA; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE SILENCING; HAPLOINSUFFICIENCY; MOUSE; MYOTUBE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SOLEUS MUSCLE; WESTERN BLOTTING;

EID: 84872678501     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2012.066357     Document Type: Article

References (32)

1. Abraham RT (2001). Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15, 2177-2196.
2. Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, Shiloh Y, Crawley JN, Ried T, Tagle D & Wynshaw-Boris A (1996). Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86, 159-171.
3. phox is critical for α-platelet-derived growth factor receptor-induced production of reactive oxygen species. J Biol Chem 283, 7864-7876.
4. Bhatti S, Kozlov S, Farooqi AA, Naqi A, Lavin M & Khanna KK (2011). ATM protein kinase: the linchpin of cellular defenses to stress. Cell Mol Life Sci 68, 2977-3006.
5. Boder E & Sedgwick R (1958). Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics 21, 526-554.
6. Boucher J, Tseng YH & Kahn CR (2010). Insulin and insulin-like growth factor-1 receptors act as ligand-specific amplitude modulators of a common pathway regulating gene transcription. J Biol Chem 285, 17235-17245.
7. Ching JK, Spears LD, Armon JL, Renth AL, Andrisse S, Collins IV RL & Fisher JS (2012). Impaired insulin-stimulated glucose transport in ATM-deficient mouse skeletal muscle. Applied Physiology, Nutrition, and Metabolism (in press).
8. Copp J, Manning G & Hunter T (2009). TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 69, 1821-1827.
9. 632 in human insulin receptor substrate-1 are important for full activation of insulin-stimulated phosphatidylinositol 3-kinase activity and translocation of GLUT4 in adipose cells. Endocrinology 142, 2833-2840.
10. Goldstein BJ, Mahadev K & Wu X (2005). Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes 54, 311-321.
11. Guo Z, Kozlov S, Lavin MF, Person MD & Paull TT (2010). ATM activation by oxidative stress. Science 330, 517-521.
12. Halaby MJ, Hibma JC, He J & Yang DQ (2008). ATM protein kinase mediates full activation of Akt and regulates glucose transporter 4 translocation by insulin in muscle cells. Cell Signal 20, 1555-1563.
13. Handayaningsih AE, Iguchi G, Fukuoka H, Nishizawa H, Takahashi M, Yamamoto M, Herningtyas EH, Okimura Y, Kaji H, Chihara K, Seino S & Takahashi Y (2011). Reactive oxygen species play an essential role in IGF-I signaling and IGF-I-induced myocyte hypertrophy in C2C12 myocytes. Endocrinology 152, 912-921.
14. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ & Smith GC (2004). Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64, 9152-9159.
15. Hiel JA, van Engelen BG, Weemaes CM, Broeks A, Verrips A, ter Laak H, Vingerhoets HM, van den Heuvel LP, Lammens M, Gabreels FJ, Last JI & Taylor AM (2006). Distal spinal muscular atrophy as a major feature in adult-onset ataxia telangiectasia. Neurology 67, 346-349.
16. 473 kinase for Akt/PKB in 3T3-L1 adipocytes. J Biol Chem 280, 40406-40416.
17. Irarrazabal CE, Burg MB, Ward SG & Ferraris JD (2006). Phosphatidylinositol 3-kinase mediates activation of ATM by high NaCl and by ionizing radiation: role in osmoprotective transcriptional regulation. Proc Natl Acad Sci U S A 103, 8882-8887.
18. Jeong I, Patel AY, Zhang Z, Patil PB, Nadella ST, Nair S, Ralston L, Hoormann JK & Fisher JS (2010). Role of ataxia telangiectasia mutated in insulin signaling of muscle-derived cell lines and mouse soleus. Acta Physiol (Oxf) 198, 465-475.
19. Kuang X, Shen J, Wong PK & Yan M (2009). Deregulation of mTOR signaling is involved in thymic lymphoma development in Atm-/- mice. Biochem Biophys Res Commun 383, 368-372.
20. O'Neill T, Dwyer AJ, Ziv Y, Chan DW, Lees-Miller SP, Abraham RH, Lai JH, Hill D, Shiloh Y, Cantley LC & Rathbun GA (2000). Utilization of oriented peptide libraries to identify substrate motifs selected by ATM. J Biol Chem 275, 22719-22727.
21. Peretz S, Jensen R, Baserga R & Glazer PM (2001). ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci U S A 98, 1676-1681.
22. Sarbassov DD, Guertin DA, Ali SM & Sabatini DM (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
23. Schneider JG, Finck BN, Ren J, Standley KN, Takagi M, Maclean KH, Bernal-Mizrachi C, Muslin AJ, Kastan MB & Semenkovich CF (2006). ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab 4, 377-389.
24. Schubert R, Reichenbach J & Zielen S (2005). Growth factor deficiency in patients with ataxia telangiectasia. Clin Exp Immunol 140, 517-519.
25. Shiloh Y (2003). ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3, 155-168.
26. Siddle K (2011). Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol 47, R1-R10.
27. Soliman GA, Acosta-Jaquez HA, Dunlop EA, Ekim B, Maj NE, Tee AR & Fingar DC (2010). mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 285, 7866-7879.
28. Ursø B, Cope DL, Kalloo-Hosein HE, Hayward AC, Whitehead JP, O'Rahilly S & Siddle K (1999). Differences in signaling properties of the cytoplasmic domains of the insulin receptor and insulin-like growth factor receptor in 3T3-L1 adipocytes. J Biol Chem 274, 30864-30873.
29. Viniegra JG, Martinez N, Modirassari P, Hernández Losa J, Parada Cobo C, Sánchez-Arévalo Lobo VJ, Aceves Luquero CI, Alvarez-Vallina L, Rámon y Cajal S, Rojas JM & Sánchez-Prieto R (2005). Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem 280, 4029-4036.
30. Watanabe R, Wei L & Huang J (2011). mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med 52, 497-500.
31. Yang DQ, Halaby MJ, Li Y, Hibma JC & Burn P (2011). Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration. Drug Discov Today 16, 332-338.
32. Yang DQ & Kastan MB (2000). Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol 2, 893-898.